Medite Cancer Diagnostics, Inc.
MDITOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$8672
P/E Ratio—
52W High$0.005
52W Low$0.0001
Medite Cancer Diagnostics, Inc.（MDIT）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · MDIT · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2017-12 | 2016-12 | 2015-12 |
|---|---|---|---|
| Revenue | |||
| Revenue | $6.81M | $9.24M | $9.89M |
| Cost of Revenue | $6.94M | $5.82M | $6.26M |
| Gross Profit | ($0.13M) | $3.42M | $3.63M |
| Gross Margin %(computed) | -1.92% | 36.98% | 36.67% |
| Operating Expenses | |||
| R&D Expenses | $1.19M | $1.48M | $1.28M |
| G&A Expenses | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $6.35M | $5.08M | $4.22M |
| Operating Income | ($6.48M) | ($1.66M) | ($0.60M) |
| Operating Margin %(computed) | -95.11% | -17.98% | -6.06% |
| Interest Income | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.85M | $0.69M | $0.20M |
| Income Before Tax | ($7.30M) | ($2.29M) | ($0.78M) |
| Income Tax Expense | ($0.49M) | ($0.13M) | $0.08M |
| Net Income | ($6.81M) | ($2.16M) | ($0.86M) |
| Net Margin %(computed) | -99.97% | -23.41% | -8.69% |
| Per Share & EBITDA | |||
| EPS (Basic) | $-0.26 | $-0.10 | $-0.04 |
| Wtd Avg Shares | 26.44M | 21.42M | 20.19M |
| EBITDA | ($6.19M) | ($1.45M) | ($0.42M) |
| EBITDA Margin %(computed) | -90.81% | -15.66% | -4.27% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Medite Cancer Diagnostics, Inc.
关于Medite Cancer Diagnostics, Inc.（MDIT）损益表
Medite Cancer Diagnostics, Inc.（MDIT）损益表数据来源于SEC Form 10-K及10-Q申报文件。2017财年，MDIT实现营收$0.01B，毛利润($0.00B)（毛利率-1.92%），净利润($0.01B)（净利率-99.97%）。
常见问题
MDIT · 4 问Medite Cancer Diagnostics, Inc.（MDIT）2017财年营收为$0.01B，同比down26.3%。
MDIT revenueMDIT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09